CTAD 2026

Ito et al

 

Preferences And Access Considerations For Clinical Adoption Of Blood-based Biomarker Tests To Confirm Amyloid-β Pathology In Early Alzheimer’s Disease: A 12-country Survey

Copies of these presentations obtained through the QR code are for personal use only and may not be used without permission from CTAD and the authors of this presentation.